fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Sanofi and Regeneron provide update on U.S. Phase II/III adaptive-designed trial in hospitalized COVID-19 patients.

Written by | 28 Apr 2020

Sanofi and Regeneron Pharmaceuticals, Inc., announced the preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating Kevzara (sarilumab) , an interleukin-6 (IL-6) receptor… read more.

Mateon Pharma submits IND to the FDA to approve new phase II study of OT 101 for the treatment of COVID-19 pandemic.

Written by | 28 Apr 2020

Mateon Therapeutics Inc.announced it has submitted an Investigational New Drug (IND) application to the FDA)to study its investigational drug, OT-101, for the treatment of COVID-19 pandemic.The proposed randomized,… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

Myovant Sciences announces publication of abstracts detailing efficacy and safety from phase III LIBERTY studies in uterine fibroids in Obstetrics & Gynecology journal.

Written by | 28 Apr 2020

Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.

BioNTech AG and Pfizer Inc., initiate a phase 1/II trial of BNT 162 vaccine to prevent COVID-19 infection.

Written by | 27 Apr 2020

BioNTech AG and Pfizer Inc. have announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/II clinical trial for BioNTech’s BNT 162 vaccine program to… read more.

Siemens Healthlineers has developed a laboratory-based total antibody test to detect the presence of SARS-CoV-2 antibodies in blood.

Written by | 25 Apr 2020

Siemens Healthineers announced it is significantly expanding its infectious disease testing capabilities to aid in the COVID-19 pandemic. Recognizing the critical need for accurate diagnostic testing to manage… read more.

ViroKey SARS-CoV-2 RT-PCR Test receives the CE mark for in vitro diagnostic test for COVD-19.- Vela Diagnostics

Written by | 25 Apr 2020

Vela Diagnostics announced that the manual version of the ViroKey SARS-CoV-2 RT-PCR Test has received the CE mark for in vitro diagnostic use. The test detects SARS-CoV-2 in… read more.

AstraZeneca + Saint Luke’s Mid America Heart Institute initiate phase III DARE-19 trial with Farxiga in COVID-19 patients.

Written by | 24 Apr 2020

AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.